Double-blind, placebo-controlled study for the effect of rutin-rich processed buckwheat (Manten-kirari) on dyslipidemia

Double-blind, placebo-controlled study for the effect of rutin-rich processed buckwheat (Manten-kirari) on dyslipidemia - Effect of rutin-rich buckwheat on dyslipidemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012507

Enrollment

Registered

2013-12-06

Start date

2013-11-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

Intake 80g of rehydratable noodle containing 50% rutin-rich buckwheat powder daily for 8 weeks. Intake 80g of rehydratable noodle containing 5% rutin-rich buckwheat powder daily for 8 weeks. Intake 80

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Subjects whose serum LDL cholesterol levels are between 120mg/dl and 180mg/dl. (2)Subjects who agree to participate in the current study with written informed consent.

Exclusion criteria

Exclusion criteria: (1)Subjects who are under medication for chronic ailments. (2)Subjects with serious diseases and infections. (3)Subjects with clinical history of gastrointestinal surgery. (4)Subjects with frequent complaints of post-menopausal symptoms. (5)Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. (6)Subjects with serious anemia. (7)Subjects with a history of allergy to medicine and food, especially buckwheat and wheat. (8)Subjects routinely on supplementation which would affect the lipid metabolism. (9)Heavy smokers and alcohol addicts, or subjects with irregular lifestyle. (10)Subjects who donate 400ml whole blood within 12 weeks or who donate plasma or platelets within 4 weeks prior to supplementation. (11)Subjects who are pregnant or under lactation, or ones who would be expected to be pregnant during the study. (12)Subjects who participate in other clinical trials within the last one month prior to the current clinical trial. (13)Subjects who are not eligible due to physician's judgment

Design outcomes

Primary

Measure	Time frame
LDL-CHO, adiponectin, visceral fat area	—

Secondary

Measure	Time frame
T-CHO, HDL-CHO, TG, fasting blood glucose, HbA1c, RLP-CHO, leptin, oxo-LDL, TBARS, hs-CRP, IL-6, TNF-alfa,CAVI and ABI score, FMD, blood pressure	—

Countries

Japan

Contacts

Public ContactDir. Prof. Jun Nishihira, M.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026